All Work

Chris Lange

Opposing Views on Gilead Hepatitis C Presentation

Gilead Sciences is a major biotech involved with the EASL conference, and two analysts are calling heads and tails in terms of what the HCV news means for the stock.

Chris Lange · 12 years ago

What to Expect From Pier 1 Earnings

Pier 1 Imports is scheduled to report its fiscal fourth-quarter financial results on Wednesday after the U.S. markets close.

Chris Lange · 12 years ago

What to Expect From Rite Aid Earnings

Rite Aid is scheduled to release its fiscal fourth-quarter financial results Wednesday morning before the markets open.

Chris Lange · 12 years ago

SEC Intercepts Ponzi Scheme

The SEC announced Tuesday that fraud charges were filed against a former NFL player who is alleged to have operated a Ponzi scheme.

Chris Lange · 12 years ago

Ballard on Track With New China Deal

Ballard Power Systems has announced that the world's first hydrogen fuel cell powered, fixed-rail electric tram was successfully demonstrated at a facility of CSR Qingdao Sifang company.

Chris Lange · 12 years ago

Is Priceline Going to $1,500?

Argus has initiated coverage of Priceline with a Buy rating and a price target that implies upside of 24% from the current share price.

Chris Lange · 12 years ago

Unlocking the Hidden Value of NRG

Merrill Lynch has made some sense of the valuation of NRG Energy and might see a classic value play with solid upside expected.

Chris Lange · 12 years ago

Is a Big Share Buyback Coming to DaVita?

DaVita Healthcare Partners has a large amount of cash on its balance sheet and it does not pay a dividend. Should investors should expect a big stock buyback?

Chris Lange · 12 years ago